APOLLOMICS, INC.

Analyst Reco. Apollomics, Inc.

Equities

APLM

KYG0411D1079

Market Closed - Nasdaq Other stock markets 16:30:00 2024-05-17 EDT			5-day change	1st Jan Change
0.3322 ^USD	-2.29%		-10.67%	-65.58%

05-08	Apollomics, Inc. Appoints Robert Lin to the Board of Directors	CI
05-08	Apollomics, Inc. announced that it has received $5.75 million in funding	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

EF Hutton Cuts Price Target on Apollomics to $6.50 From $11, Maintains Buy Rating	04-01	MT
HC Wainwright Adjusts Apollomics' Price Target to $5 From $17, Maintains Buy Rating	04-01	MT
Apollomics Inc. Announces Efficacy of Vebrelinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate of 75%	23-10-23	CI
HC Wainwright Adjusts Price Target on Apollomics to $17 From $18, Maintains Buy Rating	23-10-03	MT
EF Hutton Assumes Apollomics at Buy With $25 Price Target	23-08-23	MT
HC Wainwright Initiates Apollomics at Buy With $18 Price Target	23-06-01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW